Equities analysts expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings per share (EPS) of $0.04 for the current quarter, according to Zacks. Four analysts have made estimates for Crispr Therapeutics’ earnings, with estimates ranging from $0.01 to $0.07. Crispr Therapeutics posted earnings per share of ($0.92) in the same quarter last year, which would suggest a positive year-over-year growth rate of 104.3%. The firm is scheduled to issue its next earnings results on Monday, February 24th.
On average, analysts expect that Crispr Therapeutics will report full-year earnings of $0.65 per share for the current financial year, with EPS estimates ranging from $0.59 to $0.71. For the next year, analysts expect that the business will post earnings of ($4.64) per share, with EPS estimates ranging from ($5.38) to ($3.67). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%.
A number of analysts have recently issued reports on the company. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. BidaskClub cut Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 13th. Finally, Chardan Capital reiterated a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company. Crispr Therapeutics presently has a consensus rating of “Buy” and an average target price of $71.38.
Shares of Crispr Therapeutics stock traded down $0.38 during trading hours on Tuesday, hitting $67.50. 20,940 shares of the company’s stock traded hands, compared to its average volume of 1,072,989. The stock has a 50 day simple moving average of $63.17 and a 200-day simple moving average of $49.95. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market cap of $3.76 billion, a PE ratio of -19.54 and a beta of 3.30. Crispr Therapeutics has a twelve month low of $22.36 and a twelve month high of $74.00.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total transaction of $465,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. grew its position in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after buying an additional 906,006 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter worth approximately $21,167,000. Finally, Morgan Stanley raised its position in shares of Crispr Therapeutics by 6.1% during the 2nd quarter. Morgan Stanley now owns 284,984 shares of the company’s stock worth $13,423,000 after purchasing an additional 16,361 shares during the period. 49.82% of the stock is owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: The limitations of an equal weight rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.